Who we serve
NashBio's data products and services support teams across research and discovery, from biotech target hunting and pharma clinical development through Medtech and Healthtech companies training the algorithms inside their products.
The foundation is the same. The layers are not.
Every engagement starts from the same 4M+ patient clinical foundation. What changes is which data layers your work depends on, and how much of the analysis your team wants to run.
Life sciences
Biotech, pharma and biopharma teams use NashBio clinico-genomic data for target discovery, patient stratification, synthetic control arms and regulatory evidence.
Healthtech and Medtech
Device and software teams train, test and justify their technology on de-identified imaging, 500Hz ECG waveforms and clinical notes before it reaches a clinician.
AI applications
AI teams build and validate models on multimodal data drawn from one patient population, with the labels, reports and outcomes needed to check what a model learned.
Interested in partnering with NashBio?
Tell us what you are working on and someone from our team will be in touch.
Frequently Asked Questions
- Who uses NashBio's real-world data?
- NashBio works with biotech, pharma and biopharma companies, and with Medtech and Healthtech developers. Ten of the world's largest pharmaceutical companies are members of the Alliance for Genomic Discovery, the consortium NashBio launched with Illumina, and device and software teams use the same data to train and validate diagnostic and decision-support tools.
- Can real-world data be used to train AI and machine learning models?
- Yes. NashBio supplies de-identified imaging in DICOM format paired with radiology reports, 1.9M+ digital ECG recordings at original 500Hz sampling, and archives of unstructured clinical notes, all linked to the same patients. Teams use it to train computer vision, calibrate NLP tools, and back-test decision-support recommendations against real patient journeys.
- Does NashBio work with biotech companies, or only large pharma?
- Both. Biotech teams use NashBio data to run phenome-wide association studies across 250K+ linked genomes without building a prospective cohort first, and to construct synthetic control arms for rare disease and narrow oncology programs. Expert Services can carry the analysis where a smaller team has no in-house specialist.